11:58 AM EST - Tekmira Pharmaceuticals Corp. : said it has received a new contract with the U.S. Department of Defense Chemical and Biological Defense Program through the U.S. Army Space and Missile Defense Command, to advance an RNAi therapeutic utilizing Tekmira's lipid nanoparticle technology, SNALP, to treat Ebola virus infection, which is lethal to humans. More than 15% of the estimated value of this award will be subcontracted to U.S. businesses. Tekmira Pharmaceuticals Corp.
shares T.TKM are trading up $0.53 at $1.87.
